Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- P/B of 24.01 — trading above book value
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -30.5%
- Revenue growing at 36% annually
Harrow, Inc. - Common Stock (HROW) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.3 billion . Key value metrics: P/B ratio 24.01, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Harrow, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, HROW shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -30.5% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 4.77.
StockPik's composite Value Score for HROW is 34/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HROW reports a high gross margin of 73.6% (sector average: 33.5%) and a modest operating margin of 7.0%.
HROW shows revenue growing at 36% year-over-year, with earnings growing at 71%.